ClinicalTrials.Veeva

Menu
W

West Tennessee Research Institute | Jackson, TN

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Methotrexate
Tofacitinib
Ianalumab
Apremilast
Upadacitinib
Adalimumab
Baricitinib
Secukinumab
Deucravacitinib
Tocilizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

26 of 77 total trials

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous syst...

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Drug: Ianalumab
Drug: Placebo
Locations recently updated

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Enrolling
Sjogren's Syndrome
Drug: HZN-1116
Drug: Placebo
Locations recently updated

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously...

Enrolling
Sjogrens Syndrome
Other: Placebo
Drug: Ianalumab (VAY736)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Placebo
Biological: Risankizumab

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Enrolling
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis wh...

Active, not recruiting
Psoriatic Arthritis
Drug: Deucravacitinib
Other: Placebo

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-a...

Enrolling
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Drug: Avacopan
Drug: Standard of Care
Locations recently updated

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab
Locations recently updated

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Enrolling
Sjogren's Syndrome
Drug: Dazodalibep
Drug: Placebo

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling
Sjögren's Syndrome
Other: Placebo
Drug: Deucravacitinib

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Drug: Upadacitinib
Other: Placebo

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Placebo
Drug: Litifilimab
Locations recently updated

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at leas...

Enrolling
Obesity
Psoriatic Arthritis
Drug: Tirzepatide
Drug: Ixekizumab
Locations recently updated

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have pr...

Enrolling
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Ianalumab

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of...

Enrolling
Systemic Lupus Erythematosus
Drug: placebo
Drug: ianalumab

This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with gi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Biological: Secukinumab 150 mg
Other: Placebo

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) f...

Active, not recruiting
Polymyalgia Rheumatica
Drug: Secukinumab 150 mg
Other: Placebo to secukinumab

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the...

Enrolling
Autoimmunity, Inflammation
Biological: Secukinumab s.c. injection

Trial sponsors

Pfizer logo
Bristol-Myers Squibb (BMS) logo
Novartis logo
Amgen logo
AbbVie logo
Lilly logo
Roche logo
Janssen (J&J Innovative Medicine) logo
Biogen logo
Acceleron Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems